Agenus (AGEN) : 6 days before expiry, shorts in Agenus (AGEN) have reduced from 7,082,218 on Jul 29, 2016, to 6,974,395 on August 15, 2016. On an average, 1,235,467 shares are traded on the exchange. The outstanding bearish positions are equal to 9.5% of the float. Short sellers have covered -107,823 shares, a reduction of -1.5%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
Agenus (NASDAQ:AGEN): The stock opened at $6.08 on Wednesday but the bulls could not build on the opening and the stock topped out at $6.29 for the day. The stock traded down to $5.83 during the day, due to lack of any buying support eventually closed down at $5.85 with a loss of -3.31% for the day. The stock had closed at $6.05 on the previous day. The total traded volume was 1,404,823 shares.
In a related news, Armen Garo H, CEO of Agenus Inc, had purchased 100,000 shares on May 6, 2016. The total value of the transaction was $318,000. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).